Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs

Roger G. Perez, Masazumi Arai, Chris Richardson, Anthony Dipaula, Cynthia Siu, Naoki Matsumoto, James E K Hildreth, M. Michele Mariscalco, C. Michele Smith, Lewis Becker

Research output: Contribution to journalArticle

Abstract

Anti-CD18 monoclonal antibodies (MAb) have demonstrated variable protection against neutrophil (PMN)-mediated myocardial reperfusion injury. To identify factors contributing to this variability, open-chest dogs underwent coronary artery occlusion for 90 min followed by reperfusion for 3.5 h. Ten minutes before reperfusion the dogs received saline (n = 18) or one of three anti-CD18 MAb: MHM.23, R15.7, or PLM-2 (2, 1, and 1 mg/kg and n = 19, 8, and 4, respectively). Collateral flow was measured with radioactive microspheres, area at risk was assessed with monastral blue dye, and infarct size was measured postmortem by triphenyltetrazolium chloride. In vitro, all three MAb bound to canine PMNs, but only MHM.23 and R15.7 inhibited their adherence to keyhole limpet hemocyanin-coated plastic. In vivo, only MHM.23 and R15.7 significantly reduced infarct size after adjusting for the effect of collateral flow. MHM.23 afforded protection in dogs with moderate ischemia (epicardial collateral flow >0.1 ml · min-1 · g-1, infarct size reduced 46%) but not in dogs with more severe ischemia. Only R15.7 was effective in dogs with severe ischemia. Although MHM.23 and R15.7 produced similar inhibition of tissue PMN accumulation, as reflected by myeloperoxidase activity, R15.7 markedly inhibited H2O2 production by PMNs after exposure to platelet-activating factor, whereas MHM.23 had only a minimal effect. The effectiveness of different anti-CD18 MAb in preventing reperfusion injury appears to be 1) highly dependent on the specific anti-CD18 MAb employed, 2) predicted only partially by in vitro binding to PMNs, static in vitro tests of PMN adherence, or the extent of inhibition of PMN accumulation in vivo, 3) related more to their ability to inhibit oxidant release from activated PMNs, and 4) strongly influenced by the severity of myocardial ischemia before reperfusion.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume270
Issue number1 39-1
StatePublished - 1996

Fingerprint

Myocardial Reperfusion Injury
Anti-Idiotypic Antibodies
Monoclonal Antibodies
Dogs
Reperfusion
Ischemia
Platelet Activating Factor
Coronary Occlusion
Reperfusion Injury
Microspheres
Oxidants
Peroxidase
Plastics
Myocardial Ischemia
Canidae
Coronary Vessels
Neutrophils
Thorax
Protective Factors
In Vitro Techniques

Keywords

  • adhesion proteins
  • monoclonal antibodies
  • myocardial infarction
  • neutrophils

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs. / Perez, Roger G.; Arai, Masazumi; Richardson, Chris; Dipaula, Anthony; Siu, Cynthia; Matsumoto, Naoki; Hildreth, James E K; Mariscalco, M. Michele; Smith, C. Michele; Becker, Lewis.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 270, No. 1 39-1, 1996.

Research output: Contribution to journalArticle

Perez, RG, Arai, M, Richardson, C, Dipaula, A, Siu, C, Matsumoto, N, Hildreth, JEK, Mariscalco, MM, Smith, CM & Becker, L 1996, 'Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs', American Journal of Physiology - Heart and Circulatory Physiology, vol. 270, no. 1 39-1.
Perez, Roger G. ; Arai, Masazumi ; Richardson, Chris ; Dipaula, Anthony ; Siu, Cynthia ; Matsumoto, Naoki ; Hildreth, James E K ; Mariscalco, M. Michele ; Smith, C. Michele ; Becker, Lewis. / Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs. In: American Journal of Physiology - Heart and Circulatory Physiology. 1996 ; Vol. 270, No. 1 39-1.
@article{9dbeadf20f8a4d19835c640b7b0467a6,
title = "Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs",
abstract = "Anti-CD18 monoclonal antibodies (MAb) have demonstrated variable protection against neutrophil (PMN)-mediated myocardial reperfusion injury. To identify factors contributing to this variability, open-chest dogs underwent coronary artery occlusion for 90 min followed by reperfusion for 3.5 h. Ten minutes before reperfusion the dogs received saline (n = 18) or one of three anti-CD18 MAb: MHM.23, R15.7, or PLM-2 (2, 1, and 1 mg/kg and n = 19, 8, and 4, respectively). Collateral flow was measured with radioactive microspheres, area at risk was assessed with monastral blue dye, and infarct size was measured postmortem by triphenyltetrazolium chloride. In vitro, all three MAb bound to canine PMNs, but only MHM.23 and R15.7 inhibited their adherence to keyhole limpet hemocyanin-coated plastic. In vivo, only MHM.23 and R15.7 significantly reduced infarct size after adjusting for the effect of collateral flow. MHM.23 afforded protection in dogs with moderate ischemia (epicardial collateral flow >0.1 ml · min-1 · g-1, infarct size reduced 46{\%}) but not in dogs with more severe ischemia. Only R15.7 was effective in dogs with severe ischemia. Although MHM.23 and R15.7 produced similar inhibition of tissue PMN accumulation, as reflected by myeloperoxidase activity, R15.7 markedly inhibited H2O2 production by PMNs after exposure to platelet-activating factor, whereas MHM.23 had only a minimal effect. The effectiveness of different anti-CD18 MAb in preventing reperfusion injury appears to be 1) highly dependent on the specific anti-CD18 MAb employed, 2) predicted only partially by in vitro binding to PMNs, static in vitro tests of PMN adherence, or the extent of inhibition of PMN accumulation in vivo, 3) related more to their ability to inhibit oxidant release from activated PMNs, and 4) strongly influenced by the severity of myocardial ischemia before reperfusion.",
keywords = "adhesion proteins, monoclonal antibodies, myocardial infarction, neutrophils",
author = "Perez, {Roger G.} and Masazumi Arai and Chris Richardson and Anthony Dipaula and Cynthia Siu and Naoki Matsumoto and Hildreth, {James E K} and Mariscalco, {M. Michele} and Smith, {C. Michele} and Lewis Becker",
year = "1996",
language = "English (US)",
volume = "270",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "1 39-1",

}

TY - JOUR

T1 - Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs

AU - Perez, Roger G.

AU - Arai, Masazumi

AU - Richardson, Chris

AU - Dipaula, Anthony

AU - Siu, Cynthia

AU - Matsumoto, Naoki

AU - Hildreth, James E K

AU - Mariscalco, M. Michele

AU - Smith, C. Michele

AU - Becker, Lewis

PY - 1996

Y1 - 1996

N2 - Anti-CD18 monoclonal antibodies (MAb) have demonstrated variable protection against neutrophil (PMN)-mediated myocardial reperfusion injury. To identify factors contributing to this variability, open-chest dogs underwent coronary artery occlusion for 90 min followed by reperfusion for 3.5 h. Ten minutes before reperfusion the dogs received saline (n = 18) or one of three anti-CD18 MAb: MHM.23, R15.7, or PLM-2 (2, 1, and 1 mg/kg and n = 19, 8, and 4, respectively). Collateral flow was measured with radioactive microspheres, area at risk was assessed with monastral blue dye, and infarct size was measured postmortem by triphenyltetrazolium chloride. In vitro, all three MAb bound to canine PMNs, but only MHM.23 and R15.7 inhibited their adherence to keyhole limpet hemocyanin-coated plastic. In vivo, only MHM.23 and R15.7 significantly reduced infarct size after adjusting for the effect of collateral flow. MHM.23 afforded protection in dogs with moderate ischemia (epicardial collateral flow >0.1 ml · min-1 · g-1, infarct size reduced 46%) but not in dogs with more severe ischemia. Only R15.7 was effective in dogs with severe ischemia. Although MHM.23 and R15.7 produced similar inhibition of tissue PMN accumulation, as reflected by myeloperoxidase activity, R15.7 markedly inhibited H2O2 production by PMNs after exposure to platelet-activating factor, whereas MHM.23 had only a minimal effect. The effectiveness of different anti-CD18 MAb in preventing reperfusion injury appears to be 1) highly dependent on the specific anti-CD18 MAb employed, 2) predicted only partially by in vitro binding to PMNs, static in vitro tests of PMN adherence, or the extent of inhibition of PMN accumulation in vivo, 3) related more to their ability to inhibit oxidant release from activated PMNs, and 4) strongly influenced by the severity of myocardial ischemia before reperfusion.

AB - Anti-CD18 monoclonal antibodies (MAb) have demonstrated variable protection against neutrophil (PMN)-mediated myocardial reperfusion injury. To identify factors contributing to this variability, open-chest dogs underwent coronary artery occlusion for 90 min followed by reperfusion for 3.5 h. Ten minutes before reperfusion the dogs received saline (n = 18) or one of three anti-CD18 MAb: MHM.23, R15.7, or PLM-2 (2, 1, and 1 mg/kg and n = 19, 8, and 4, respectively). Collateral flow was measured with radioactive microspheres, area at risk was assessed with monastral blue dye, and infarct size was measured postmortem by triphenyltetrazolium chloride. In vitro, all three MAb bound to canine PMNs, but only MHM.23 and R15.7 inhibited their adherence to keyhole limpet hemocyanin-coated plastic. In vivo, only MHM.23 and R15.7 significantly reduced infarct size after adjusting for the effect of collateral flow. MHM.23 afforded protection in dogs with moderate ischemia (epicardial collateral flow >0.1 ml · min-1 · g-1, infarct size reduced 46%) but not in dogs with more severe ischemia. Only R15.7 was effective in dogs with severe ischemia. Although MHM.23 and R15.7 produced similar inhibition of tissue PMN accumulation, as reflected by myeloperoxidase activity, R15.7 markedly inhibited H2O2 production by PMNs after exposure to platelet-activating factor, whereas MHM.23 had only a minimal effect. The effectiveness of different anti-CD18 MAb in preventing reperfusion injury appears to be 1) highly dependent on the specific anti-CD18 MAb employed, 2) predicted only partially by in vitro binding to PMNs, static in vitro tests of PMN adherence, or the extent of inhibition of PMN accumulation in vivo, 3) related more to their ability to inhibit oxidant release from activated PMNs, and 4) strongly influenced by the severity of myocardial ischemia before reperfusion.

KW - adhesion proteins

KW - monoclonal antibodies

KW - myocardial infarction

KW - neutrophils

UR - http://www.scopus.com/inward/record.url?scp=13344280357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13344280357&partnerID=8YFLogxK

M3 - Article

VL - 270

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 1 39-1

ER -